Campus Digest

HKBU and CUHK jointly develop new drug JCM-16021 for the treatment of Irritable Bowel Syndrome

05 Mar 2019

 
{{currentSlide}} / 2
Professor Bian Zhaoxiang (left) and Professor Justin Wu explain the research development process and the effectiveness of JCM-16021
The JCM-16021 contains Rhizoma Atractylodis Macrocephalae (白朮), Radix Paeoniae Lactiflorae (白芍), Cortex Magnoliae Officinalis (/厚樸), Semen coicis Lachryma-jobi (薏苡仁), Polygonaceae (火炭母), Fructus Terminaliae Chebulae (訶子) and Rhizoma Corydalis Yanhusuo (延胡索)

 

Researchers from Hong Kong Baptist University (HKBU) and the Chinese University of Hong Kong (CUHK) have developed a new formula, called JCM-16021, for the treatment of Irritable bowel syndrome (IBS). The novel drug will be subjected to a large-scale clinical trial with the aim of providing an additional effective therapy option for patients.

 

For more details, please visit: https://www.hkbu.edu.hk/en/whats-new/press-release/2019/0305-hkbu-and-cuhk-jointly-develop-new-drug-jcm-16021-for-the-treatment-of-irritable-bowel-syndrome.html